TerminatedPhase 3

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

Stopped: Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed consent.

Netherlands80 participantsStarted 2008-02

Plain-language summary

The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium, severity of delirium, length of ICU/hospital stay and side effects between the different interventions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Older than 18 years * Diagnosed as hypoactive delirium * Informed consent given Exclusion Criteria: * Pregnancy * Epilepsy * M. Parkinson * Lewy-body dementia * Prolonged QT-time * Known allergy to the medicinals used * Renal replacement therapy * Hepatic encephalopathy * Hyperthyroid * Glaucoma * Previous suicide attempts * Syndrome of Gilles de la Tourette * Patients which cannot receive the medication oral or through a nasogastric tube

What they're measuring

duration of delirium

Timeframe: Days

Trial details

NCT IDNCT00599287

SponsorUMC Utrecht

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-05

View on ClinicalTrials.gov More Delirium trials